Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2026-02-02
Disclosure Type: Provisional Operating Performance (Fair Disclosure)
💡 3-Second Summary
Alteogen delivered an extraordinary performance for the full year of 2025, recording revenue of KRW 202.1B and operating profit of KRW 114.7B, which represents more than a twofold increase in sales and a 3.7-fold surge in operating profit compared to the previous year.
📊 1. [Key Disclosure Content & Summary of Major Figures]
- Revenue: KRW 202.1B (202,116 million KRW)
- An increase of 117.4% compared to the previous year’s (2024) performance of 92,969 million KRW.
- Operating Profit: KRW 114.7B (114,797 million KRW)
- An increase of 274.8% compared to the previous year’s (2024) performance of 30,630 million KRW.
- Undisclosed Items: Profit before income tax from continuing operations and Net Profit were not included in this disclosure and will be re-disclosed after the final settlement.
- Reason for Changes: The official disclosure document does not provide specific reasons or detailed breakdowns regarding the cause of this performance growth.
📈 2. [Expert View: What This Disclosure Means for Investors]
- Indicators of Improving Profitability: The fact that the growth rate of operating profit (274.8%) overwhelmingly exceeds the growth rate of revenue (117.4%) implies a potential shift toward high-margin business structures or enhanced operational efficiency. The structural integrity of the data is confirmed as revenue strictly exceeds operating profit.
- Shift in Financial Fundamental: Rather than a short-term, one-off event, this reflects continuous annual growth in both top-line scale and bottom-line profitability. This data could be interpreted as a potential indicator that the company’s fundamental is structurally strengthening.
- Risks to Monitor (Potential Adjustments): Since these figures are ‘provisional’ and have not yet undergone a final accounting audit by an external auditor, they may be subject to change depending on the final audit results. Furthermore, since net income figures are omitted, investors are advised to exercise caution and cross-check the final indicators through upcoming disclosures.
📝 Editor’s Comment (by K-STOCK Editor)
When a biotech firm transitions from evaluating potential to demonstrating actual commercial scalability through financial numbers, the market relevance is clear. Alteogen’s provisional results show a strong operating leverage effect that surpasses its top-line revenue growth rate. However, because the net income metrics remain undisclosed, a measured perspective is required until the final audited reports and subsequent disclosures are made public. This commentary outlines general market observations and does not constitute buying or selling signals.
📢 Disclaimer & Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!